Brilinta 'more cost-effective than Plavix', says AstraZeneca as it awaits US decision
This article was originally published in Scrip
AstraZeneca has revealed new health economics data from a sub-study of the PLATO trial showing that treating a broad spectrum of acute coronary syndrome (ACS) patients with ticagrelor (Brilique/Brilinta) was more cost-effective than treatment with the generic clopidogrel (Sanofi/Bristol-Myers Squibb's blockbuster Plavix, which comes off patent next year).
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.